Florent Aptel1, Alain M Bron, Yves Lachkar, Cédric Schweitzer. 1. *Department of Ophthalmology, University Hospital of Grenoble, Grenoble †Department of Ophthalmology, University Hospital of Dijon, Dijon ‡Institut du Glaucome, Fondation Hôpital Saint-Joseph, Paris §Department of Ophthalmology, CHU Bordeaux ∥Bordeaux Population Health Research Center, Team LEHA, University Bordeaux, Inserm, Bordeaux, France.
Abstract
PURPOSE: To evaluate the effect of treatment escalation on the rate of visual field progression in patients with primary open-angle glaucoma (POAG). PATIENTS AND METHODS: Multicenter database study. We reviewed the electronic records of 171 patients with POAG under medical hypotensive treatment who underwent 5 consecutive visits 6 months apart before and after medical treatment escalation or additive laser trabeculoplasty. We calculated the rate of visual field progression (mean deviation change per year) before and after treatment escalation. RESULTS: The mean duration of follow-up was 5.1±0.5 years and the mean number of visual field examinations was 10.2±0.2. In 139 eyes with medical treatment escalation, the rate of progression was significantly reduced [from -0.57 to -0.29 dB/y; P=0.022; intraocular pressure (IOP) reduction 11.1%]. In detail, the rate of progression was significantly reduced after escalation from mono to dual therapy, dual to triple therapy, and from mono to triple therapy (-0.35 to -0.24 dB/y, P=0.018; -1.01 to -0.48 dB/y, P=0.038; -1.04 to -0.35 dB/y, P=0.020, respectively). In 32 eyes with additive laser trabeculoplasty, the rate of progression was significantly reduced (-0.60 to -0.24 dB/y; P=0.014; IOP reduction 9.4%). CONCLUSIONS: Medical treatment escalation or additive laser trabeculoplasty significantly reduced the rate of visual field progression in POAG. Larger IOP reduction has a greater probability of reducing glaucoma progression.
PURPOSE: To evaluate the effect of treatment escalation on the rate of visual field progression in patients with primary open-angle glaucoma (POAG). PATIENTS AND METHODS: Multicenter database study. We reviewed the electronic records of 171 patients with POAG under medical hypotensive treatment who underwent 5 consecutive visits 6 months apart before and after medical treatment escalation or additive laser trabeculoplasty. We calculated the rate of visual field progression (mean deviation change per year) before and after treatment escalation. RESULTS: The mean duration of follow-up was 5.1±0.5 years and the mean number of visual field examinations was 10.2±0.2. In 139 eyes with medical treatment escalation, the rate of progression was significantly reduced [from -0.57 to -0.29 dB/y; P=0.022; intraocular pressure (IOP) reduction 11.1%]. In detail, the rate of progression was significantly reduced after escalation from mono to dual therapy, dual to triple therapy, and from mono to triple therapy (-0.35 to -0.24 dB/y, P=0.018; -1.01 to -0.48 dB/y, P=0.038; -1.04 to -0.35 dB/y, P=0.020, respectively). In 32 eyes with additive laser trabeculoplasty, the rate of progression was significantly reduced (-0.60 to -0.24 dB/y; P=0.014; IOP reduction 9.4%). CONCLUSIONS: Medical treatment escalation or additive laser trabeculoplasty significantly reduced the rate of visual field progression in POAG. Larger IOP reduction has a greater probability of reducing glaucoma progression.
Authors: Aakriti G Shukla; C Gustavo De Moraes; George A Cioffi; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Jeffrey M Liebmann Journal: J Glaucoma Date: 2020-06 Impact factor: 2.503
Authors: Daniel C Terveen; Steven R Sarkisian; Steven D Vold; Deepan Selvadurai; Blake K Williamson; Deborah G Ristvedt; Adam R Bleeker; Kavita Dhamdhere; Jaime E Dickerson Journal: Int Ophthalmol Date: 2022-10-13 Impact factor: 2.029
Authors: Yolandi van der Merwe; Matthew C Murphy; Jeffrey R Sims; Muneeb A Faiq; Xiao-Ling Yang; Leon C Ho; Ian P Conner; Yu Yu; Christopher K Leung; Gadi Wollstein; Joel S Schuman; Kevin C Chan Journal: Neurotherapeutics Date: 2021-04-13 Impact factor: 7.620
Authors: Jose J Garcia-Medina; Javier Benitez-Del-Castillo; Iñaki Rodríguez-Agirretxe; Fernando Lopez-Lopez; Antonio Moreno-Valladares Journal: J Ocul Pharmacol Ther Date: 2022-02-28 Impact factor: 2.850